Other CSC-targeting therapies under investigation include monoclonal antibodies against CSC surface markers, for example adecatumumab targeting EpCAM in prostate cancer, and therapies that disrupt pathways enriched in CSCs, such as the Wnt, Notch, and Hedgehog pathways (Oberneder et al., 2006; Le et al., 2015; Norsworthy et al., 2019; Yang et al., 2020). This evidence concerns the gene EPCAM and prostate carcinoma.